Literature DB >> 22122363

A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder.

Robert J Gregory1, Susan Chlebowski2, David Kang2, Anna L Remen2, Maureen G Soderberg2, Jason Stepkovitch2, Subhdeep Virk2.   

Abstract

A randomized controlled trial was conducted to determine whether a manual-based psychodynamic treatment, labeled dynamic deconstructive psychotherapy (DDP), would be feasible and effective for individuals with co-occurring borderline personality disorder (BPD) and alcohol use disorder. Thirty participants were assessed every 3 months during a year of treatment with either DDP or treatment as usual (TAU) in the community. DDP participants showed statistically significant improvement in parasuicide behavior, alcohol misuse, institutional care, depression, dissociation, and core symptoms of BPD, and treatment retention was 67% to 73%. Although TAU participants received higher average treatment intensity, they showed only limited change during the same period. The results support the feasibility, tolerability, and efficacy of DDP for the co-occurring subgroup and highlight the need for further research. (PsycINFO Database Record (c) 2010 APA, all rights reserved).

Entities:  

Year:  2008        PMID: 22122363     DOI: 10.1037/0033-3204.45.1.28

Source DB:  PubMed          Journal:  Psychotherapy (Chic)        ISSN: 0033-3204


  17 in total

Review 1.  Is longer-term psychodynamic psychotherapy more effective than shorter-term therapies? Review and critique of the evidence.

Authors:  Sunil S Bhar; Brett D Thombs; Monica Pignotti; Marielle Bassel; Lisa Jewett; James C Coyne; Aaron T Beck
Journal:  Psychother Psychosom       Date:  2010-04-29       Impact factor: 17.659

2.  Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study.

Authors:  Björn Philips; Peter Wennberg; Per Konradsson; Johan Franck
Journal:  Eur Addict Res       Date:  2018-01-19       Impact factor: 3.015

3.  The effectiveness of psychodynamic psychotherapies: An update.

Authors:  Peter Fonagy
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

Review 4.  Borderline personality disorder and comorbid addiction: epidemiology and treatment.

Authors:  Thorsten Kienast; Jutta Stoffers; Felix Bermpohl; Klaus Lieb
Journal:  Dtsch Arztebl Int       Date:  2014-04-18       Impact factor: 5.594

Review 5.  Treatment for comorbid borderline personality disorder and alcohol use disorders: a review of the evidence and future recommendations.

Authors:  Mayumi O Gianoli; J Serrita Jane; Erin O'Brien; Elizabeth Ralevski
Journal:  Exp Clin Psychopharmacol       Date:  2012-06-11       Impact factor: 3.157

Review 6.  Psychological therapies for people with borderline personality disorder.

Authors:  Jutta M Stoffers; Birgit A Völlm; Gerta Rücker; Antje Timmer; Nick Huband; Klaus Lieb
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

7.  Deficits in emotion-regulation skills predict alcohol use during and after cognitive-behavioral therapy for alcohol dependence.

Authors:  Matthias Berking; Matthias Margraf; David Ebert; Peggilee Wupperman; Stefan G Hofmann; Klaus Junghanns
Journal:  J Consult Clin Psychol       Date:  2011-06

8.  Randomized trial of dual-focused vs. single-focused individual therapy for personality disorders and substance dependence.

Authors:  Samuel A Ball; Lisa M Maccarelli; Donna M LaPaglia; Mark J Ostrowski
Journal:  J Nerv Ment Dis       Date:  2011-05       Impact factor: 2.254

9.  Psychopharmacology Today: Where are We and Where Do We Go From Here?

Authors:  Thomas L Schwartz
Journal:  Mens Sana Monogr       Date:  2010-01

10.  Psychological therapies for people with borderline personality disorder.

Authors:  Ole Jakob Storebø; Jutta M Stoffers-Winterling; Birgit A Völlm; Mickey T Kongerslev; Jessica T Mattivi; Mie S Jørgensen; Erlend Faltinsen; Adnan Todorovac; Christian P Sales; Henriette E Callesen; Klaus Lieb; Erik Simonsen
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.